DIC is an acquired, life-threatening syndrome of systemic coagulation activation secondary to an underlying condition, resulting in simultaneous microvascular thrombosis and consumptive hemorrhagic coagulopathy. [1-2] The 2025 ISTH updated definition emphasizes its dynamic progression from pre-DIC → early-phase (compensated) DIC → overt DIC, with classification into thrombotic and hemorrhagic phenotypes. [2-3]
1. History
- Key HPI questions: Onset and character of bleeding (mucosal, wound oozing, IV site bleeding), signs of organ dysfunction (altered mental status, oliguria, dyspnea), recent fever/infection, trauma, surgery, or obstetric events
- Symptom characterization: Bleeding is the most common presentation (~90% of cases); only 5–10% present with thrombotic features alone (e.g., digital ischemia, purpura fulminans) [4-5]
- Timing/triggers: Acute onset in sepsis, trauma, obstetric emergencies; subacute/chronic in malignancy (especially acute promyelocytic leukemia, adenocarcinomas) [1][6]
- Associated symptoms: Petechiae, ecchymoses, hematuria, GI bleeding, hemoptysis, signs of end-organ damage
- Important negatives: No prior bleeding disorder, no anticoagulant use, no recent heparin exposure (to distinguish from HIT), no family history of coagulopathy
2. Alarm Features
- Profuse hemorrhage from multiple sites (IV lines, surgical wounds, mucosal surfaces) [4]
- Purpura fulminans — symmetric, rapidly progressive purpuric skin lesions with necrosis (classically meningococcemia)
- Acute organ failure — renal failure, ARDS, hepatic dysfunction, altered mental status from microvascular thrombosis [4]
- Hemodynamic instability/shock — reported as a suggestive clinical feature in 63% of clinicians surveyed [5]
- Rapidly falling platelet count or fibrinogen on serial labs — indicates decompensation
- Worsening ISTH DIC score on repeat assessment
3. Medications
- Medication contributors to DIC: Chemotherapy (especially ATRA-related differentiation syndrome in APL), recreational drugs, certain toxins (snake venom) [6-7]
- Common treatments:
- FFP 15–25 mL/kg for active bleeding with prolonged PT/aPTT >1.5× normal [4][8]
- Platelet transfusion to maintain >50 × 10⁹/L if bleeding; >20 × 10⁹/L if not bleeding [4][6]
- Cryoprecipitate or fibrinogen concentrate for fibrinogen <1.5 g/L [4][8]
- VTE prophylaxis with LMWH or UFH in non-bleeding patients [9-10]
- Therapeutic heparin only when thrombotic features predominate [9]
- Contraindicated medications:
- Antifibrinolytics (tranexamic acid) are generally contraindicated in DIC — exception: markedly hyperfibrinolytic states (e.g., APL, early trauma) [6][9]
- Long-acting antiplatelet agents should generally be discontinued unless strongly indicated (e.g., recent PCI) [8]
- Cautions: Activated protein C, antithrombin concentrates, and recombinant thrombomodulin have not demonstrated robust mortality benefit in RCTs, though antithrombin may be considered in sepsis-associated DIC [4][9][11]
4. Diet
- Not directly applicable in the acute setting
- Hydration: Aggressive IV fluid resuscitation as part of hemodynamic support and treatment of underlying cause (e.g., sepsis)
- Nutritional support: Early enteral nutrition in ICU patients per standard critical care protocols; no DIC-specific dietary modifications
5. Review of Systems
- Hematologic: Bleeding from any site, bruising, petechiae
- Neurologic: Altered mental status, focal deficits (microvascular thrombosis)
- Renal: Oliguria, hematuria, flank pain
- Pulmonary: Dyspnea, hemoptysis (ARDS, pulmonary hemorrhage)
- GI: Hematemesis, melena, abdominal pain
- Dermatologic: Purpura, acral cyanosis, skin necrosis
- Obstetric (if applicable): Vaginal bleeding, uterine tenderness, fetal distress
6. Collateral History and Family History
- Collateral: Recent hospitalizations, surgeries, infections, chemotherapy, blood product transfusions, obstetric complications, trauma mechanism
- Family history: Generally not contributory (DIC is acquired), but rule out inherited bleeding disorders (hemophilia, vWD) that may mimic or coexist
- Social context: IV drug use (endocarditis → sepsis → DIC), snake bites, environmental exposures [6-7]
7. Risk Factors
8. Differential Diagnosis
- Thrombotic thrombocytopenic purpura (TTP): Thrombocytopenia + MAHA, but PT/aPTT typically normal; ADAMTS13 activity <10% is diagnostic
- Hemolytic uremic syndrome (HUS): Thrombocytopenia + MAHA + renal failure; coagulation tests usually normal
- Heparin-induced thrombocytopenia (HIT): Platelet drop 5–10 days post-heparin; thrombosis predominates; 4Ts score and anti-PF4 antibodies distinguish
- Severe liver disease/hepatic coagulopathy: Prolonged PT, low fibrinogen, thrombocytopenia — but D-dimer elevation is less dramatic; clinical context differs [4]
- Massive transfusion/dilutional coagulopathy: History of >10 units pRBCs; treated with cryoprecipitate, platelets, FFP — antifibrinolytics are appropriate here (unlike DIC) [6]
- Trauma-induced coagulopathy (TIC): Early hyperfibrinolytic phase distinct from DIC; TXA is indicated early in trauma [12]
- Primary fibrinolysis: Rare; low fibrinogen and elevated FDPs but normal/near-normal platelet count
- HELLP syndrome: Overlaps with obstetric DIC; distinguished by elevated LFTs and hemolysis pattern
9. Past Medical History
- Prior episodes of DIC or thrombotic events
- Known malignancy (especially hematologic)
- Chronic liver disease (baseline coagulopathy complicates interpretation)
- Recent surgery or invasive procedures
- Obstetric history (prior abruption, preeclampsia)
- Immunocompromised states increasing infection risk
10. Physical Exam
- Vital signs: Tachycardia, hypotension, fever (or hypothermia in sepsis), tachypnea
- Skin: Petechiae, purpura, ecchymoses, acral cyanosis, wound/IV site oozing, purpura fulminans, skin necrosis [5]
- Mucous membranes: Gingival bleeding, epistaxis
- Abdomen: Hepatosplenomegaly (malignancy), uterine tenderness (obstetric causes)
- Extremities: Digital ischemia, gangrene (thrombotic DIC phenotype)
- Neurologic: Altered sensorium, focal deficits
- Focused exam for underlying cause: Surgical wounds, abscess, signs of septic source
11. Lab Studies
Core labs for ISTH DIC scoring: [2-3][13]
- Platelet count — typically decreased; serial decline is key
- PT/INR — prolonged (>3 seconds above normal scores points)
- D-dimer / FDPs — elevated; a normal D-dimer effectively excludes DIC; 2025 ISTH criteria: >3× ULN = 2 points, >7× ULN = 3 points [3][7]
- Fibrinogen — low (<1 g/L scores 1 point), though may be falsely normal/elevated as an acute-phase reactant in sepsis [14]
- aPTT — prolonged (supportive but not in ISTH score)
Additional labs:
- Peripheral blood smear — schistocytes (microangiopathic hemolytic anemia) [14]
- Antithrombin activity — low levels (<47%) associated with higher mortality; may guide antithrombin replacement [15]
- LDH, haptoglobin, reticulocyte count — assess for hemolysis
- Lactate, blood cultures, comprehensive metabolic panel — evaluate underlying cause and organ dysfunction
- Type and screen — anticipate transfusion needs
12. Imaging
- No specific imaging diagnoses DIC — imaging is directed at identifying the underlying cause
- CT abdomen/pelvis for intra-abdominal sepsis, abscess, or malignancy
- CT head if neurologic symptoms (to evaluate for intracranial hemorrhage or thrombosis)
- Chest X-ray/CT for pneumonia, ARDS
- Obstetric ultrasound for placental abruption, retained products
- Imaging is unnecessary for DIC diagnosis itself — it is a clinical and laboratory diagnosis
13. Special Tests
- ISTH Overt DIC Score (≥5 = overt DIC): Based on platelet count, D-dimer/FDP, PT prolongation, and fibrinogen level [3][13]
- Sepsis-Induced Coagulopathy (SIC) Score: Detects early/compensated DIC in sepsis; uses platelet count, PT-INR, and SOFA score; ~60% of sepsis patients meet SIC criteria, nearly all of whom progress to overt DIC if untreated [11][16]
- Quick DIC Score (PT-INR × D-dimer / platelet count): Proposed simplified index with high diagnostic accuracy [17]
- Viscoelastic testing (TEG/ROTEM): Point-of-care assessment of clot formation, strength, and fibrinolysis — results available in 5–10 minutes; particularly useful in obstetric and trauma DIC for guiding transfusion [18]
- ADAMTS13 activity: To rule out TTP when thrombocytopenia + MAHA is present
The following figure illustrates ROTEM and TEG parameters used in point-of-care assessment of DIC:
14. ECG
- No DIC-specific ECG findings
- ECG indicated to evaluate for:
- Myocardial ischemia from microvascular thrombosis or hemodynamic instability
- Hyperkalemia (from renal failure, massive transfusion, tissue necrosis)
- Arrhythmias secondary to electrolyte derangements or shock
- Monitor for right heart strain pattern if concurrent PE is suspected
15. Assessment
- DIC is always secondary to an underlying condition — identifying and treating the trigger is the single most important intervention [1][4][9]
- Severity stratification: The ISTH DIC score correlates with clinical outcomes and mortality. The 2025 ISTH update introduces phase-based classification (pre-DIC → early-phase → overt) to enable earlier intervention [2-3][19]
- Phenotype matters: Thrombotic DIC (microvascular thrombosis, organ dysfunction) vs. hemorrhagic DIC (consumptive bleeding) — management differs [3]
- Mortality: Remains high; pooled mortality in sepsis-associated DIC is ~44% by ISTH criteria. SOFA score ≥12 and antithrombin <47% predict >40% 28-day mortality [15-16]
- Complications: Multiorgan failure, massive hemorrhage, limb ischemia/gangrene, ARDS, renal failure, stroke
16. Treatment Plan
Initial stabilization
- ABCs, large-bore IV access, hemodynamic resuscitation
- Activate massive transfusion protocol if profuse hemorrhage
Cornerstone — treat the underlying cause: [1][4][9]
- Antibiotics and source control for sepsis
- Delivery for obstetric causes (abruption, HELLP)
- Chemotherapy for malignancy (ATRA + arsenic trioxide for APL)
- Surgical intervention for tissue injury/abscess
Blood product replacement (for bleeding or high bleeding risk): [4][8][10]
Anticoagulation: [9-10]
- VTE prophylaxis with LMWH or UFH recommended in non-bleeding patients (even with DIC) until platelets <30 × 10⁹/L or active bleeding
- Therapeutic heparin only when thrombotic features predominate (e.g., digital ischemia, purpura fulminans)
- Antithrombin concentrates and recombinant thrombomodulin may be considered in sepsis-associated DIC, though robust RCT evidence of mortality benefit is lacking [9][11]
Avoid
- Antifibrinolytics (TXA) in general DIC — exception for hyperfibrinolytic states (APL, early trauma) [9]
- Activated protein C — withdrawn from market; no mortality benefit and increased bleeding [4]
17. Disposition
- All patients with overt DIC require ICU admission — continuous monitoring, serial coagulation labs (q6–8h initially), and hemodynamic support [10]
- Early-phase/compensated DIC (SIC): ICU or step-down unit with close monitoring; ~60% of sepsis patients meet SIC criteria and are at risk for progression [11]
- Specialist consultation triggers:
- Hematology — for diagnostic uncertainty, refractory coagulopathy, malignancy-associated DIC
- Surgery/OB — for source control, obstetric emergencies
- Critical care — for all patients with organ dysfunction
- Discharge criteria: Resolution of underlying cause, normalizing coagulation parameters (improving platelet count and PT-INR are the strongest predictors of survival), no active bleeding, hemodynamic stability [20]
18. Follow Up / Return Precautions
- Inpatient monitoring: Serial ISTH DIC scores (q6–12h) to track progression or resolution; DIC resolution by day 3–6 is associated with significantly improved survival [20]
- Post-discharge follow-up:
- Repeat CBC and coagulation panel within 1–2 weeks
- Follow-up with hematology if malignancy-related or recurrent DIC
- Monitor for late thrombotic complications (VTE risk persists after DIC resolution)
- Return precautions: New or worsening bleeding, signs of infection (fever, chills), shortness of breath, altered mental status, skin color changes (cyanosis, new purpura), decreased urine output
- Expected recovery: Dependent on resolution of the underlying cause; coagulation parameters typically normalize within days once the trigger is controlled. Mortality remains high even with treatment, particularly in sepsis-associated DIC [16][21]
The following figure from the NEJM provides a diagnostic algorithm for evaluating bleeding in ICU patients, including the DIC pathway:
References
1. How I Treat Disseminated Intravascular Coagulation. — Levi M, Scully M. Blood. 2018.
2. Updated Definition and Scoring of Disseminated Intravascular Coagulation in 2025: Communication From the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. — Iba T, Levy JH, Maier CL, et al. Journal of Thrombosis and Haemostasis : JTH. 2025.
3. Introducing the New Definition and Diagnostic Criteria of Disseminated Intravascular Coagulation Released by the International Society on Thrombosis and Haemostasis in 2025. — Iba T, Maier CL, Scarlatescu E, Levy JH. Seminars in Thrombosis and Hemostasis. 2025.
4. Bleeding and Coagulopathies in Critical Care. — Hunt BJ. The New England Journal of Medicine. 2014.
5. Global Practice and Challenges in the Diagnosis and Management of Disseminated Intravascular Coagulation: Communication From the ISTH SSC Subcommittee on Disseminated Intravascular Coagulation. — Nwagha TU, Hajjaj OI, Levy JH, et al. Journal of Thrombosis and Haemostasis : JTH. 2026.
6. Hematologic Emergencies: Recognition and Initial Management. — Jones DE, Walker JJ, Abellada AMP. American Family Physician. 2024.
7. A Test in Context: D-Dimer. — Weitz JI, Fredenburgh JC, Eikelboom JW. Journal of the American College of Cardiology. 2017.
8. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. — Bikdeli B, Madhavan MV, Jimenez D, et al. Journal of the American College of Cardiology. 2020.
9. Guidance for Diagnosis and Treatment of DIC From Harmonization of the Recommendations From Three Guidelines. — Wada H, Thachil J, Di Nisio M, et al. Journal of Thrombosis and Haemostasis : JTH. 2013.
10. Supportive Management Strategies for Disseminated Intravascular Coagulation. An International Consensus. — Squizzato A, Hunt BJ, Kinasewitz GT, et al. Thrombosis and Haemostasis. 2016.
11. Communication From the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis on Sepsis-Induced Coagulopathy in the Management of Sepsis. — Iba T, Levi M, Thachil J, et al. Journal of Thrombosis and Haemostasis : JTH. 2023.
12. Mechanisms and Management of the Coagulopathy of Trauma and Sepsis: Trauma-Induced Coagulopathy, Sepsis-Induced Coagulopathy, and Disseminated Intravascular Coagulation. — Iba T, Helms J, Neal MD, Levy JH. Journal of Thrombosis and Haemostasis : JTH. 2023.
13. Treatment for Disseminated Intravascular Coagulation in Patients With Acute and Chronic Leukemia. — Martí-Carvajal AJ, Anand V, Solà I. The Cochrane Database of Systematic Reviews. 2015.
14. Evaluation of the International Society on Thrombosis & Haemostasis Scoring System & Its Modifications in Diagnosis of Disseminated Intravascular Coagulation: A Pilot Study From Southern India. — Muddana PS, Kar SS, Kar R. The Indian Journal of Medical Research. 2022.
15. Risk Stratification Utilizing Sequential Organ Failure Assessment (SOFA) Score, Antithrombin Activity, and Demographic Data in Sepsis-Associated Disseminated Intravascular Coagulation (DIC). — Iba T, Maier CL, Tanigawa T, Levy JH. Scientific Reports. 2023.
16. A Comparison of Disseminated Intravascular Coagulation Scoring Systems and Their Performance to Predict Mortality in Sepsis Patients: A Systematic Review and Meta-Analysis. — Kiya GT, Abebe G, Mekonnen Z, et al. PloS One. 2024.
17. Proposal of Quick Diagnostic Criteria for Disseminated Intravascular Coagulation. — Wada H, Yamamoto A, Tomida M, et al. Journal of Clinical Medicine. 2022.
18. Disseminated Intravascular Coagulation. — Martina Burn, Hillary Hosier, Nazli Hossain, et al. Critical Care Obstetrics, 7th Edition. 2024.
19. Disseminated Intravascular Coagulation. — Gando S, Levi M, Toh CH. Nature Reviews. Disease Primers. 2016.
20. Disseminated Intravascular Coagulation Resolution as a Surrogate Outcome for Mortality in Sepsis-Associated Disseminated Intravascular Coagulation. — Wada T, Tanigawa T, Shiko Y, Yamakawa K, Gando S. Thrombosis Research. 2025.
21. Disseminated Intravascular Coagulation and Its Immune Mechanisms. — Popescu NI, Lupu C, Lupu F. Blood. 2022.